Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression

CONTEXT: Immune checkpoint blockades (ICBs) have been approved widely to treat various malignancies. Autoimmune diabetes mellitus, which can be caused by programmed cell death protein 1 (PD-1) inhibitors, is rare. Sintilimab, a monoclonal anti-PD-1 antibody, has been approved in China for the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Liang, Zou, Xiuwen, Chen, Yiwen, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472830/
https://www.ncbi.nlm.nih.gov/pubmed/32973816
http://dx.doi.org/10.3389/fimmu.2020.02076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472830/
https://www.ncbi.nlm.nih.gov/pubmed/32973816
http://dx.doi.org/10.3389/fimmu.2020.02076

Ejemplares similares